SS Innovations International Inc(SSII) - 2025 Q3 - Quarterly Results

Revenue Growth - Revenue increased 192.5% year over year to $12.8 million from $4.4 million in Q3 2024[5] - Total revenue for the first nine months of 2025 increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024[5] - Total revenue for Q3 2025 reached $12,829,349, a significant increase of 192% compared to $4,386,516 in Q3 2024[20] - For the nine months ended September 30, 2025, total revenue was $27,950,264, an increase of 123% from $12,533,335 in the same period of 2024[21] Gross Profit and Margin - Gross profit rose 166.0% to $6.2 million from $2.3 million in Q3 2024[5] - Gross profit for Q3 2025 was $6,164,936, compared to $2,317,407 in Q3 2024, reflecting a gross margin improvement[20] System Installations and Surgeries - SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in Q3 2024[5] - SSi Mantra installations for the first nine months of 2025 totaled 63, up 152.0% from 25 installations in the first nine months of 2024[10] - Cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures[5] Net Loss and Financial Performance - Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in Q3 2024[5] - The net loss for Q3 2025 was $3,717,964, compared to a net loss of $3,245,483 in Q3 2024, indicating a worsening of financial performance despite revenue growth[20] Cash and Liquidity - Cash and cash equivalents totaled $5.7 million, excluding restricted cash[5] - Cash and cash equivalents at the end of Q3 2025 were $12,039,247, up from $6,152,262 at the end of Q3 2024, showing improved liquidity[23] Operating and Research Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $20,626,239, slightly down from $21,620,651 in the same period of 2024[21] - Research and development expenses for the nine months ended September 30, 2025, were $2,295,014, an increase from $1,729,834 in the same period of 2024[21] Foreign Currency Impact - The company reported a foreign currency translation loss of $480,822 in Q3 2025, compared to a loss of $59,087 in Q3 2024[20] Future Plans - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025[6] - The company aims for European Union CE marking certification in the first half of 2026[6] Share Dilution - The weighted average diluted shares increased to 202,856,501 in Q3 2025 from 181,885,269 in Q3 2024, reflecting dilution from equity financing[20]